Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Facial Bradykinesia
JNNP 84:681-685, Bologna, M.,et al, 2013
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
Ophthalmologic Features of Parkinson's Disease
Neurol 62:177-180, Biousse,V.,et al, 2004
The Relationship of Essential Tremor to Other Movement Disorders:Report on 678 Patients
Ann Neurol 35, 717-7231994., Koller,W.C.,et al, 1994
Movement Disorders in Alcoholism:A Review
Neurol 40:741-746, Neiman,J.,et al, 1990
Extrapyramidal Involvement in Rett's Syndrome
Neurol 40:293-295, FitzGerald,P.M.,et al, 1990
Metoclopramide-Induced Movement Disorders
Arch Int Med 149:2486-2492, Miller,L.G.&Jankovic,J., 1989
Extrapyramidal Side-Effects Of Metoclopramide
Lancet 2:1254-1255, Kataria,M.,et al, 1981
Parkinson's Disease
In Handbk of Clinical Neurology, Vinken, P. J. & Bruyn, G. W. , Ed, North-Holland Publ Co, Amsterdam, 6:173, 1968. Selby, G., 1968
A 58-year-old Man with Hand Tremor and Episodes of Neck Pain
Neurol 93:557-561, Urso, D.,et al, 2019
Thalamic Deep Brain Stimulation for Tremor in Parkinson Disease, Essential Tremor, and Dystonia
Neurol 89:1416-1423, Cury, R.G.,et al, 2017
Clinical, Genetic, and Radiological Features of Extrapyramidal Movement Disorders in Mitochondrial Disease
JAMA Neurol 73:668-674, Martikainen, M.H.,et al, 2016
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Incidence and Pathology of Synucleinopathies and Tauopathies Related to Parkinsonism
JAMA Neurol 70:859-866, Savica, R.,et al, 2013
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Diagnosis and Treatment of Psychogenic Parkinsonism
JNNP 82:1300-1303, Jankovic, J., 2011
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Deep Brain Stimulation
Neurologist 13:237-252, Kem,DS. &Kumar,R., 2007
The Parkinsons Complex: Parkinsonism Is Just the Tip of the Iceberg
Ann Neurol 59:591-596, Langston,J.W., 2006
The Pull Test:A History
Mov Disord 21:894-899, Hunt,A.L.,et al, 2006
Pallidal vs Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease
Arch Neurol 62:554-560,533, Anderson,V.C.,et al, 2005
Post-Stroke Movement Disorders; Report of 56 Patients
JNNP 75:1568-1574, Alarcon,F.,et al, 2004
Does This Patient Have Parkinson Disease?
JAMA 289:347-353, Rao,G.,et al, 2003
Therapies for Movement Disorders
Arch Neurol 59:699-702, Goetz,C.G &Hinson,V.K., 2002
Involuntary Movements After Anterior Cerebral Artery Territory Infarction
Stroke 32:258-261, Kim,J.S., 2001
Parkinsonism as the Presenting Manifestation of HIV Infection: Improvement on HAART
Neurol 56:278-279, Hersh,B.P.,et al, 2001
MR Imaging Findings After Stereotactic Radiosurgery Using the Gamma Knife
AJR 176:1589-1595, Friedman,D.P.,et al, 2001
Deep-Brain Stimulation of the Subthalamic Nucleus or the Pars Interna of the Globus Pallidus in Parkinson's Disease
NEJM 345:956-963, The Deep-Brain Stimulation for Parkinson's Disease, 2001
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Neurologic Side Effects in Neuroleptic-Naive Patients Treated with Haloperidol or Risperidone
Neurol 52:782-785, Rosebush,P.I.&Mazurek,M.F., 1999
Parkinsonism after Taking Ecstasy
NEJM 340:1443, Mintzer,S.,et al, 1999
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Clinical Presentation and Pharmacological Therapy in Corticobasal Degeneration
Arch Neurol 55:957-961, Kompoliti,K.,et al, 1998
Mortality in People Taking Selegiline:Observational Study
BMJ 317:252-254, Thorogood,M.,et al, 1998
Olanzapine Can Worsen Parkinsonism
Neurol 50:1183-1184, Jimenez-Jimenez,F.J.,et al, 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Drug-Induced Movement Disorders
Neurol Clin 16:125-139, Diederich,N.J. & Goetz,C.G., 1998
Surgery for Parkinson's Disease
JNNP 62:2-8, Obeso,J.A.,et al, 1997
Low-Dose Clozapine Improves Dyskinesias in Parkinson's Disease
Neurol 48:658-662, Durif,F.,et al, 1997
Mortality from Parkinson Disease
Arch Neurol 54:260-264, Louis,E.D.,et al, 1997
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Tolcapone in Stable Parkinson's Disease:Efficacy and Safety of Long-Term Treatment
Neurol 49:665-671, Waters,C.H.,et al, 1997
A Survey of Antidepressant Drug Use in Parkinson's Disease
Neurol 49:1168-1170, Richard,I.H.,et al, 1997
Bent Spine Syndrome
JNNP 60:51-54, Serratrice,G.,et al, 1996
Prevalence of Parkinsonian Signs and Associated Mortality in a Community Population of Older People
NEJM 334:71-76, Bennett,D.A.,et al, 1996